NCSM

On the surface NCSM looks like a screaming value: a 5.2x P/E, 0.6x sales, net income up 260% to $23.7M, and 18.8% ROE. But the earnings math doesn't hold together — net income of $23.7M sits well above operating income of just $10.5M, and net margin (12.9%) is more than double operating margin (5.7%). That gap means the reported EPS of $8.65 (and the flattering 5.2x P/E) is being lifted by below-the-line items, not operating strength. With a -$235M accumulated deficit on the books, the most likely driver is a non-recurring deferred-tax benefit and/or equity income from the 50% Repeat Precision JV — neither of which is a clean, repeatable earnings stream. Strip that out and you're paying for a business that earns a thin ~5.7% operating margin on $184M of revenue.

What genuinely supports ownership is the balance sheet and cash generation. Liabilities/equity is just 0.30x, cash is $36.7M (+41.9%) against negligible debt, and operating cash flow of $22.2M against only $1.2M of capex throws off roughly $21M of free cash — an ~18% FCF yield on the $114M market cap. Revenue has compounded from $142M (2023) to $184M (2025) and the company swung from persistent losses to real profitability, aided by the tuck-in of ResMetrics ($7.1M) to deepen tracer diagnostics. This is a well-financed, asset-light, cyclically-recovered operator, not a distressed one.